Global Oral Biologics Market Overview:
Global Oral Biologics Market is expected to grow at a significant rate during the forecast period 2026-2035, with 2024 as the base year.
Global Oral Biologics Market Report 2026 comes with the extensive industry analysis by Introspective Market Research with development components, patterns, flows and sizes. The report also calculates present and past market values to forecast potential market management through the forecast period between 2026-2035, with base year as 2025. This research study of Oral Biologics involved the extensive usage of both primary and secondary data sources. This includes the study of various parameters affecting the industry, including the government policy, market environment, competitive landscape, historical data, present trends in the market, technological innovation, upcoming technologies and the technical progress in related industry.
Scope of the Oral Biologics Market:
The Oral Biologics Market Research report incorporates value chain analysis for each of the product type. Value chain analysis offers in-depth information about value addition at each stage.The study includes drivers and restraints for Oral Biologics Market along with their impact on demand during the forecast period. The study also provides key market indicators affecting thegrowth of the market. Research report includes major key player analysis with shares of each player inside market, growth rate and market attractiveness in different endusers/regions. Our study Oral Biologics Market helps user to make precise decision in order to expand their market presence and increase market share.
By Type, Oral Biologics market has been segmented into:
Glucagon-like Peptide 1 (GLP-1
By Application, Oral Biologics market has been segmented into:
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS
Regional Analysis:
North America (U.S., Canada, Mexico)
Europe (Germany, U.K., France, Italy, Russia, Spain, Rest of Europe)
Asia-Pacific (China, India, Japan, Singapore, Australia, New Zealand, Rest of APAC)
South America (Brazil, Argentina, Rest of SA)
Middle East & Africa (Turkey, Saudi Arabia, Iran, UAE, Africa, Rest of MEA)
Competitive Landscape:
Competitive analysis is the study of strength and weakness, market investment, market share, market sales volume, market trends of major players in the market.The Oral Biologics market study focused on including all the primary level, secondary level and tertiary level competitors in the report. The data generated by conducting the primary and secondary research.The report covers detail analysis of driver, constraints and scope for new players entering the Oral Biologics market.
Top Key Players Covered in Oral Biologics market are:
Novo Nordisk A/S
Biocon Limited
Oramed Pharmaceuticalsinc.
Rani Therapeutics
Entera Bio Ltd.
AbbVie Inc.
Enteris BioPharmainc.
Chiasmainc. and Allena Pharmaceuticalsinc.
Chapter 1: Introduction
1.1 Scope and Coverage
Chapter 2:Executive Summary
Chapter 3: Market Landscape
3.1 Market Dynamics
3.1.1 Drivers
3.1.2 Restraints
3.1.3 Opportunities
3.1.4 Challenges
3.2 Market Trend Analysis
3.3 PESTLE Analysis
3.4 Porter's Five Forces Analysis
3.5 Industry Value Chain Analysis
3.6 Ecosystem
3.7 Regulatory Landscape
3.8 Price Trend Analysis
3.9 Patent Analysis
3.10 Technology Evolution
3.11 Investment Pockets
3.12 Import-Export Analysis
Chapter 4: Oral Biologics Market by Type
4.1 Oral Biologics Market Snapshot and Growth Engine
4.2 Oral Biologics Market Overview
4.3 Glucagon-like Peptide 1 (GLP-1
4.3.1 Introduction and Market Overview
4.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
4.3.3 Key Market Trends, Growth Factors and Opportunities
4.3.4 Glucagon-like Peptide 1 (GLP-1: Geographic Segmentation Analysis
Chapter 5: Oral Biologics Market by Application
5.1 Oral Biologics Market Snapshot and Growth Engine
5.2 Oral Biologics Market Overview
5.3 Diabetes
5.3.1 Introduction and Market Overview
5.3.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.3.3 Key Market Trends, Growth Factors and Opportunities
5.3.4 Diabetes: Geographic Segmentation Analysis
5.4 Hyperoxaluria
5.4.1 Introduction and Market Overview
5.4.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.4.3 Key Market Trends, Growth Factors and Opportunities
5.4.4 Hyperoxaluria: Geographic Segmentation Analysis
5.5 Acromegaly
5.5.1 Introduction and Market Overview
5.5.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.5.3 Key Market Trends, Growth Factors and Opportunities
5.5.4 Acromegaly: Geographic Segmentation Analysis
5.6 Irritable Bowel Syndrome (IBS
5.6.1 Introduction and Market Overview
5.6.2 Historic and Forecasted Market Size in Value USD and Volume Units (2026-2035F)
5.6.3 Key Market Trends, Growth Factors and Opportunities
5.6.4 Irritable Bowel Syndrome (IBS: Geographic Segmentation Analysis
Chapter 6: Company Profiles and Competitive Analysis
6.1 Competitive Landscape
6.1.1 Competitive Benchmarking
6.1.2 Oral Biologics Market Share by Manufacturer (2023)
6.1.3 Industry BCG Matrix
6.1.4 Heat Map Analysis
6.1.5 Mergers and Acquisitions
6.2 NOVO NORDISK A/S
6.2.1 Company Overview
6.2.2 Key Executives
6.2.3 Company Snapshot
6.2.4 Role of the Company in the Market
6.2.5 Sustainability and Social Responsibility
6.2.6 Operating Business Segments
6.2.7 Product Portfolio
6.2.8 Business Performance
6.2.9 Key Strategic Moves and Recent Developments
6.2.10 SWOT Analysis
6.3 BIOCON LIMITED
6.4 ORAMED PHARMACEUTICALSINC.
6.5 RANI THERAPEUTICS
6.6 ENTERA BIO LTD.
6.7 ABBVIE INC.
6.8 ENTERIS BIOPHARMAINC.
6.9 CHIASMAINC. AND ALLENA PHARMACEUTICALSINC.
Chapter 7: Global Oral Biologics Market By Region
7.1 Overview
7.2. North America Oral Biologics Market
7.2.1 Key Market Trends, Growth Factors and Opportunities
7.2.2 Top Key Companies
7.2.3 Historic and Forecasted Market Size by Segments
7.2.4 Historic and Forecasted Market Size By Type
7.2.4.1 Glucagon-like Peptide 1 (GLP-1
7.2.5 Historic and Forecasted Market Size By Application
7.2.5.1 Diabetes
7.2.5.2 Hyperoxaluria
7.2.5.3 Acromegaly
7.2.5.4 Irritable Bowel Syndrome (IBS
7.2.6 Historic and Forecast Market Size by Country
7.2.6.1 US
7.2.6.2 Canada
7.2.6.3 Mexico
7.3. Eastern Europe Oral Biologics Market
7.3.1 Key Market Trends, Growth Factors and Opportunities
7.3.2 Top Key Companies
7.3.3 Historic and Forecasted Market Size by Segments
7.3.4 Historic and Forecasted Market Size By Type
7.3.4.1 Glucagon-like Peptide 1 (GLP-1
7.3.5 Historic and Forecasted Market Size By Application
7.3.5.1 Diabetes
7.3.5.2 Hyperoxaluria
7.3.5.3 Acromegaly
7.3.5.4 Irritable Bowel Syndrome (IBS
7.3.6 Historic and Forecast Market Size by Country
7.3.6.1 Bulgaria
7.3.6.2 The Czech Republic
7.3.6.3 Hungary
7.3.6.4 Poland
7.3.6.5 Romania
7.3.6.6 Rest of Eastern Europe
7.4. Western Europe Oral Biologics Market
7.4.1 Key Market Trends, Growth Factors and Opportunities
7.4.2 Top Key Companies
7.4.3 Historic and Forecasted Market Size by Segments
7.4.4 Historic and Forecasted Market Size By Type
7.4.4.1 Glucagon-like Peptide 1 (GLP-1
7.4.5 Historic and Forecasted Market Size By Application
7.4.5.1 Diabetes
7.4.5.2 Hyperoxaluria
7.4.5.3 Acromegaly
7.4.5.4 Irritable Bowel Syndrome (IBS
7.4.6 Historic and Forecast Market Size by Country
7.4.6.1 Germany
7.4.6.2 UK
7.4.6.3 France
7.4.6.4 Netherlands
7.4.6.5 Italy
7.4.6.6 Russia
7.4.6.7 Spain
7.4.6.8 Rest of Western Europe
7.5. Asia Pacific Oral Biologics Market
7.5.1 Key Market Trends, Growth Factors and Opportunities
7.5.2 Top Key Companies
7.5.3 Historic and Forecasted Market Size by Segments
7.5.4 Historic and Forecasted Market Size By Type
7.5.4.1 Glucagon-like Peptide 1 (GLP-1
7.5.5 Historic and Forecasted Market Size By Application
7.5.5.1 Diabetes
7.5.5.2 Hyperoxaluria
7.5.5.3 Acromegaly
7.5.5.4 Irritable Bowel Syndrome (IBS
7.5.6 Historic and Forecast Market Size by Country
7.5.6.1 China
7.5.6.2 India
7.5.6.3 Japan
7.5.6.4 South Korea
7.5.6.5 Malaysia
7.5.6.6 Thailand
7.5.6.7 Vietnam
7.5.6.8 The Philippines
7.5.6.9 Australia
7.5.6.10 New Zealand
7.5.6.11 Rest of APAC
7.6. Middle East & Africa Oral Biologics Market
7.6.1 Key Market Trends, Growth Factors and Opportunities
7.6.2 Top Key Companies
7.6.3 Historic and Forecasted Market Size by Segments
7.6.4 Historic and Forecasted Market Size By Type
7.6.4.1 Glucagon-like Peptide 1 (GLP-1
7.6.5 Historic and Forecasted Market Size By Application
7.6.5.1 Diabetes
7.6.5.2 Hyperoxaluria
7.6.5.3 Acromegaly
7.6.5.4 Irritable Bowel Syndrome (IBS
7.6.6 Historic and Forecast Market Size by Country
7.6.6.1 Turkey
7.6.6.2 Bahrain
7.6.6.3 Kuwait
7.6.6.4 Saudi Arabia
7.6.6.5 Qatar
7.6.6.6 UAE
7.6.6.7 Israel
7.6.6.8 South Africa
7.7. South America Oral Biologics Market
7.7.1 Key Market Trends, Growth Factors and Opportunities
7.7.2 Top Key Companies
7.7.3 Historic and Forecasted Market Size by Segments
7.7.4 Historic and Forecasted Market Size By Type
7.7.4.1 Glucagon-like Peptide 1 (GLP-1
7.7.5 Historic and Forecasted Market Size By Application
7.7.5.1 Diabetes
7.7.5.2 Hyperoxaluria
7.7.5.3 Acromegaly
7.7.5.4 Irritable Bowel Syndrome (IBS
7.7.6 Historic and Forecast Market Size by Country
7.7.6.1 Brazil
7.7.6.2 Argentina
7.7.6.3 Rest of SA
Chapter 8 Analyst Viewpoint and Conclusion
8.1 Recommendations and Concluding Analysis
8.2 Potential Market Strategies
Chapter 9 Research Methodology
9.1 Research Process
9.2 Primary Research
9.3 Secondary Research
Oral Biologics Scope:
|
Report Data
|
Oral Biologics Market
|
|
Oral Biologics Market Size in 2025
|
USD XX million
|
|
Oral Biologics CAGR 2025 - 2032
|
XX%
|
|
Oral Biologics Base Year
|
2024
|
|
Oral Biologics Forecast Data
|
2025 - 2032
|
|
Segments Covered
|
By Type, By Application, And by Regions
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Key Companies Profiled
|
Novo Nordisk A/S, Biocon Limited, Oramed Pharmaceuticalsinc., Rani Therapeutics, Entera Bio Ltd., AbbVie Inc., Enteris BioPharmainc., Chiasmainc. and Allena Pharmaceuticalsinc..
|
|
Key Segments
|
By Type
Glucagon-like Peptide 1 (GLP-1
By Applications
Diabetes
Hyperoxaluria
Acromegaly
Irritable Bowel Syndrome (IBS
|
